Matrix Capital, an employee-owned hedge fund, led a $157m Series A funding round in GentiBio, an operator of a biotherapeutics company. Other investors include Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, Novartis Venture Fund, and Seattle Children's Research Institute. "Tregs play a vital role in controlling immune responses but are a rare and heterogenous population that is challenging to isolate and purify at scale. GentiBio engineered Tregs created from abundant autologous and allogeneic T cell sources have the potential to overcome scalability and phenotypic inconsistency issues that are intrinsic to Tregs sorted from peripheral blood. With the Series A financing, we are focused on advancing our programs with a uniquely scalable manufacturing process that produces stable and disease specific engineered Tregs that are also tunable once infused in patients," Adel Nada, GentiBio President and CEO.